Point-of-care antigen test earns FDA emergency use authorization
The Food and Drug Administration Monday authorized the emergency use of the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2.
The test is the second antigen diagnostic to earn an emergency use authorization from FDA and can be used in patient care settings approved for CLIA high or moderate complexity or waived testing.
However, the test’s emergency use is limited to authorized laboratories using the BD Veritor Plus Analyzer Instrument.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
The Senate Health, Education, Labor and Pensions Committee today 17-3 to pass as amended the Pandemic and All-Hazards Preparedness and Response Act (S. 2333),…
Headline
The Food and Drug Administration’s vaccine advisory committee June 15 voted unanimously to recommend updating the current COVID-19 vaccine composition for…
Headline
The first data on the safety of a third mRNA COVID-19 vaccine dose among young children show that a third dose is safe for children ages 6 months to 5 years…